Medincell's UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
Wednesday, Jan 29, 2025 9:50 am ET
1min read 
Medincell, a clinical and commercial-stage biopharmaceutical licensing company, has witnessed remarkable success with its long-acting injectable technology, BEPO®, in its first full year of commercialization. The company's flagship product, UZEDY® (risperidone LAI), a long-acting injectable for treating schizophrenia in adults, has surged to $117 million in sales in 2024, according to Teva Pharmaceuticals' latest results. This impressive performance marks a significant milestone for Medincell and its partner, Teva, who have collaborated to bring this innovative treatment to market.
UZEDY®'s success can be attributed to several factors, including its high adherence rates, particularly among patients with unmet social needs, as demonstrated in real-world data analysis. The product's positive clinical data and real-world evidence have helped build credibility and increase prescriber confidence, driving market acceptance and sales growth. Teva's effective marketing strategies and distribution channels have also played a crucial role in UZEDY®'s commercial success.
Medincell's partnership with Teva has been instrumental in driving UZEDY®'s sales and market penetration. Teva's dynamism and marketing strategies have contributed to the product's strong performance in the United States. In November 2024, Teva raised its sales forecast for UZEDY® by 25%, reflecting the company's confidence in the product's market potential. Teva's revised 2024 outlook for UZEDY® sales is $100 million, up from the initial forecast of $80 million. The company's U.S. net sales year-to-date in 2024 reached $75 million, with $35 million in sales in the third quarter alone.
Medincell's success with UZEDY® has opened doors for potential collaborations on other long-acting injectable therapies. The company's strategic co-development and licensing agreement with AbbVie, announced in April 2024, highlights Medincell's potential to collaborate with leading pharmaceutical companies and foundations. This partnership could lead to the development of up to six long-acting injectable therapies across various therapeutic areas, further expanding Medincell's global footprint.
In conclusion, Medincell's UZEDY® has surged to $117 million in sales in its first full year of commercialization, driven by high adherence rates, positive clinical data, and Teva's effective marketing strategies. The company's partnership with Teva has been crucial in driving UZEDY®'s success, and Medincell's strategic collaborations with other pharmaceutical companies position it for continued growth and expansion in the global biopharmaceutical market.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
